About
Systemically delivered Immune-Stimulating Antibody Conjugates
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBiotech
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
455
By Phase
PHASE1/PHASE2: 2PHASE2: 1PHASE1: 1
By Status
TERMINATED: 2RECRUITING: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06921837Lead Sponsor
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
PHASE1/PHASE2Recruiting
122 participants
Started: May 26, 2025 · Completed: May 31, 2029
NCT05954143Lead Sponsor
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
PHASE2Terminated
11 participants
Started: Nov 30, 2023 · Completed: Sep 25, 2024
NCT06052852Lead Sponsor
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
PHASE1Active, not recruiting
147 participants
Started: Oct 11, 2023 · Completed: Mar 31, 2028
NCT04278144Lead Sponsor
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
PHASE1/PHASE2Terminated
175 participants
Started: Feb 24, 2020 · Completed: Feb 14, 2025
Locations (1)
Headquarters
Redwood City, CA, United States
Map
Loading map...